Results 81 to 90 of about 15,139,370 (299)

Neurological complications of immune checkpoint inhibitor therapy: a multidisciplinary case review

open access: yesНеврология, нейропсихиатрия, психосоматика
Immunotherapy using immune checkpoint inhibitors (ICIs) has demonstrated efficacy in treating a wide range of oncological diseases, but the use of this group of drugs is associated with the risk of developing serious immune-related adverse events (irAEs).
I. Yu. Oganesyan   +8 more
doaj   +1 more source

Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective There are limited real‐world data regarding the safety and effectiveness of onasemnogene abeparvovec (OA; Zolgensma) infusion, a one‐time gene replacement therapy, for Japanese patients with spinal muscular atrophy (SMA). We aimed to improve understanding of the real‐world outcomes for OA in Japan.
Kayoko Saito   +8 more
wiley   +1 more source

Multimodality imaging of endocrine immune related adverse events: a primer for radiologists

open access: yes, 2018
Immune-related endocrine adverse events occur in up to one third of patients treated with immune checkpoint inhibitors. The purpose of this article is to provide a comprehensive review of the multimodality imaging features of the different immune-related
Hina J. Shah   +5 more
core   +1 more source

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand   +5 more
wiley   +1 more source

Clinical and Modifiable Factors Associated With Disability and Relapse in MOGAD: A Multicentre Cohort Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Factors associated with relapse course and disability in myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) remain incompletely understood. Objectives To identify clinical and modifiable factors associated with relapse and disability in MOGAD. Methods In this ambispective multicentre cohort study using data from
Yingtao Wang   +23 more
wiley   +1 more source

Neurological Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors

open access: yesBiomedicines
The use of immune checkpoint inhibitors (ICIs) for the treatment of various advanced and aggressive types of malignancy has significantly increased both survival and long-term remission rates.
Sotiria Stavropoulou De Lorenzo   +9 more
doaj   +1 more source

Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors [PDF]

open access: yes
Although immune checkpoint inhibitors have greatly improved cancer therapy, they also cause immune-related adverse events, including a wide range of inflammatory side effects resulting from excessive immune activation.
Maeda, Osamu, Liang, Yao, Ando, Yuichi
core   +2 more sources

Dynamic Gut Microbiota Changes in Patients with Advanced Malignancies Experiencing Secondary Resistance to Immune Checkpoint Inhibitors and Immune-Related Adverse Events

open access: yes, 2023
Dynamic Gut Microbiota Changes in Patients with Advanced Malignancies Experiencing Secondary Resistance to Immune Checkpoint Inhibitors and Immune-Related Adverse Events 16S rRNA gene sequencing ...
Yanlin Zeng (14427331)
core   +1 more source

Predictive Value of Composite Inflammatory Markers for Stroke Prognosis: A Prospective Cohort Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Novel composite inflammatory markers' role in stroke prognosis is understudied, and the best predictor is unclear, requiring further exploration. Objectives This study aimed to systematically evaluate the associations of 6 novel composite inflammatory markers on stroke prognosis.
Bing Wu   +7 more
wiley   +1 more source

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients

open access: yes, 2019
Shi Zhou,* Samrat Khanal,* Haijun Zhang Department of Oncology, Zhongda Hospital, Medical School of Southeast University, Nanjing, Jiangsu, People’s Republic of China *These authors contributed equally to this work Purpose: The aim of this study
Zhou S, Zhang H, Khanal S
core  

Home - About - Disclaimer - Privacy